Case-based surveillance of antimicrobial resistance with full susceptibility profiles.
Journal
JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
14
4
2020
pubmed:
14
4
2020
medline:
14
4
2020
Statut:
ppublish
Résumé
Surveillance of antimicrobial resistance (AMR) is essential for clinical decision-making and for public health authorities to monitor patterns in resistance and evaluate the effectiveness of interventions and control measures. Existing AMR surveillance is typically based on reports from hospital laboratories and public health laboratories, comprising reports of pathogen frequencies and resistance frequencies among each species detected. Here we propose an improved framework for AMR surveillance, in which the unit of surveillance is patients with specific conditions, rather than biological samples of a particular type. In this 'case-based' surveillance, denominators as well as numerators will be clearly defined with clinical relevance and more comparable at the local, national and international level. In locations with sufficient resources, individual-based data on patient characteristics and full antibiotic susceptibility profiles would provide high-quality evidence for monitoring resistant pathogens of clinical importance, clinical treatment of infections and public health responses to outbreaks of infections with resistant bacteria.
Identifiants
pubmed: 32280945
doi: 10.1093/jacamr/dlz070
pii: dlz070
pmc: PMC7134534
doi:
Types de publication
Journal Article
Langues
eng
Pagination
dlz070Subventions
Organisme : NIGMS NIH HHS
ID : U54 GM088558
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
Références
J Glob Antimicrob Resist. 2019 Mar;16:17-27
pubmed: 30145271
Respirology. 2017 Oct;22(7):1288-1299
pubmed: 28681941
Elife. 2018 Dec 18;7:
pubmed: 30560781
PLoS Pathog. 2019 May 13;15(5):e1007763
pubmed: 31083687
Antimicrob Agents Chemother. 2005 May;49(5):1965-72
pubmed: 15855520
Science. 2016 Mar 18;351(6279):1263-4
pubmed: 26989235
Emerg Infect Dis. 2013 Oct;19(10):1699-701
pubmed: 24050656
Microbiol Mol Biol Rev. 2015 Mar;79(1):101-16
pubmed: 25652543
Lancet Infect Dis. 2005 Apr;5(4):242-50
pubmed: 15792742
J Antimicrob Chemother. 2018 Jun 1;73(6):1700-1707
pubmed: 29394363
Lancet Infect Dis. 2019 Jan;19(1):56-66
pubmed: 30409683
Am J Epidemiol. 2019 Apr 1;188(4):734-742
pubmed: 30608516
Nat Med. 2003 Apr;9(4):424-30
pubmed: 12627227
Clin Infect Dis. 2017 Jul 1;65(1):37-45
pubmed: 28510723
JAMA. 2010 Aug 11;304(6):641-8
pubmed: 20699455
PLoS Med. 2017 Jul 7;14(7):e1002344
pubmed: 28686231
J Clin Microbiol. 2017 Dec 26;56(1):
pubmed: 29093105
Lancet Infect Dis. 2015 Dec;15(12):1438-49
pubmed: 26411518
J Antimicrob Chemother. 2017 May 1;72(5):1469-1477
pubmed: 28137940
Int J Infect Dis. 2005 Sep;9(5):262-73
pubmed: 16023881
J Antimicrob Chemother. 2018 Apr 1;73(4):844-851
pubmed: 29340609
Lancet Infect Dis. 2018 Mar;18(3):e99-e106
pubmed: 29102325